Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GATA6 Amplification Is Associated With Improved Survival in TP53-Mutated Unresectable Pancreatic Cancer.

Pancreas - 1 Apr 2025

Zhou Edward, Yang Jung-In, Habowski Amber N, Deschênes Astrid, Belleau Pascal, Ha Taehoon, Tzanavaris Chris J, Boyd Jeff, Hollweg Christopher A, Zhu Xinhua, Tuveson David A, King Daniel A

Abstract excerpt

OBJECTIVES: GATA6 expression is recognized as a favorable prognostic marker of pancreatic cancer, whereas TP53 is a poor prognostic marker. We evaluated treatment outcomes by genetic alterations in TP53 and GATA6 to determine the prognostic and predictive impact of co-alterations. MATERIALS AND METHODS: A single institution retrospective analysis was performed on patients diagnosed with pancreatic ductal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GATA6 Transcription Factor

Share to Gene Amplification

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Progression-Free Survival

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 40262102
DOI: 10.1097/MPA.0000000000002431
PMCID: PMC12143463

Genes

GATA6
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GATA6 Amplification Is Associated With Improved Survival in TP53-Mutated Unresectable Pancreatic Cancer.PMID 40262102Read ↗

<i>GATA6</i>amplification is associated with improved survival of<i>TP53</i>-mutated pancreatic cancerSemantic proximity Read ↗

Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary CancerSemantic proximity Read ↗

GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic CancerSemantic proximity Read ↗

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery.Semantic proximity Read ↗

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaSemantic proximity Read ↗

Presurgical ablative radiation associates with local control and immune response in pancreatic cancerSemantic proximity Read ↗

GATA6: A Pan-Cancer Transcription-Factor Biomarker Linking Diagnosis, Prognosis, and Anti- Tumour ImmunitySemantic proximity Read ↗

GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancerSemantic proximity Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database.Semantic proximity Read ↗

Exploratory analysis of gene aberrations and chemotherapy response: findings from a real-world database in Japan.Semantic proximity Read ↗

GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.